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Background: Colistin resistant Pseudomonas aeruginosa have rarely been reported in cystic fibrosis (CF) patients.
Methods: We performed a 17-year prospective study on colistin susceptibility and compared our findings with clinical variables.
Results: The first outbreak started in 1995 and lasted 5 years. It involved 27 CF patients who had inhaled colistin twice daily for a median of
10 years. Colistin resistant isolates persisted in individual patients for a median of 75 days after colistin was withdrawn.
A second outbreak started in 2004. It involved 40 patients, 17 of whom were the same as in the first outbreak. Most resistant isolates belonged
to two major clones that had similar genotypes in the two outbreaks. The P. aeruginosa isolates were all non-mucoid and they appeared in a group
of chronically infected patients that had been admitted to the same ward for antibiotic treatment and had been followed at the same week-days in
the outpatient clinic.
Patients were individually isolated to avoid cross-infection and colistin inhalation was avoided in the CF outpatient clinic and in the ward after
both outbreaks. Since 2004, no further spread has been observed.
Conclusion: It is important that the colistin resistant clones do not spread to non-infected patients since colistin is an important antibiotic for
eradication of initial and intermittent P. aeruginosa colonisation.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Colistin resistance; P. aeruginosa; Cystic fibrosis; Outbreak1. Introduction
Chronic Pseudomonas aeruginosa lung infection develops in
most patients with cystic fibrosis (CF) and is usually preceded by☆ Preliminary data were presented at the 26th European Cystic Fibrosis
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American CFConference, Anaheim, California, U.S.A., October 16–19, 2003 and
were published in abstract form in Pediatr. Pulmonology 2003; Suppl. 25, 304.
⁎ Corresponding author. Department of Clinical Microbiology 9301,
Rigshospitalet, Juliane Maries, Vej 22, DK-2100 Copenhagen Ø, Denmark.
Tel.:+45 3545 4973x6411, fax:+45 3545 6412.
E-mail address: hkj@cochrane.dk (H.K. Johansen).
1569-1993/$ - see front matter © 2008 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2008.02.003a stage of intermittent colonisation [1]. Once the bacteria have
established a chronic biofilm infection in the lungs, they can
hardly ever be eradicated, although aggressive therapy with
different antibiotic combinations and different routes of delivery
can temporarily postpone the progression of the lung disease and
prolong the life of the patients [2,3]. Since 1984, all chronically
infected Danish CF patients have inhaled 2 million units of
polymyxin E (colistin, 1 mg colistin base=30,000 units) twice
daily between the regular intravenous antibiotic courses in order
to maintain pulmonary function and decrease chronic inflamma-
tion within the respiratory tract [4]. Moreover, in an attempt to
postpone chronic infection, the routine use of early aggressive
treatment (inhaled colistin and oral ciprofloxacin for three weeksd by Elsevier B.V. All rights reserved.
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aeruginosa was introduced in 1989 [5,6].
Polymyxins are cyclic cationic antimicrobial peptides that are
highly active against many Gram-negative bacteria, including
P. aeruginosa. They exert their bactericidal activity through dis-
ruption of the cell membrane leading to leakage of cell contents
and cell death. This is achieved at least in part by binding to
lipopolysaccharide (LPS), a major component of the Gram-
negative cell surface, through interactions with phosphates and
fatty acids of LPS core and lipid A moieties [7,8]. The operon
pmrH-M is directly controlled by pmrAB, and the gene products
are responsible for the synthesis of N4-aminoarabinose that binds
to lipid A and reduces binding of polymyxins to LPS, whereby
resistance arises [9].
Although outbreaks of multi-resistant P. aeruginosa have
been reported in other settings [10], there has, to our knowledge,
been only one paper, from the United Kingdom, reporting a
small outbreak of colistin resistant P. aeruginosa among pa-
tients with CF [11]. This is surprising because colistin is com-
monly used for inhalation and intravenous therapy in CF
patients worldwide [12–15].
This paper reports on a biphasic spread of colistin resistant
non-mucoid P. aeruginosa among chronically infected CF pa-
tients in our centre. The course of the outbreak was presumably
facilitated by the daily use of colistin inhalation for the intensive
treatment of chronic P. aeruginosa infections [16].
2. Patients and methods
2.1. General care
The Copenhagen CF Centre was established in 1968 [17,18].
Since 1971 all patients have been followed monthly in the
outpatient clinic for clinical status, pulmonary function and bac-
teriological investigations of lower respiratory tract secretions.
From 1976, all patients with chronic P. aeruginosa infection
have been treated electively every 3 months with a 2-week
intravenous antibiotic course. Cohort isolation was introduced in
1981 and further expanded in 1982 subsequent to an epidemic
spread of a multi-resistant non-mucoid strain of P. aeruginosa
among patients with chronic P. aeruginosa infection [19], who
were hospitalized in the same ward for regular i.v. courses of
anti-pseudomonal chemotherapy [20]. The cohorts consist of 1)
patients chronically infected with multi-resistant P. aeruginosa
(i.e. resistant to two or more different antimicrobial classes) [19],
2) patients chronically infected with P. aeruginosa with natural,
wild-type susceptibility to antibiotics, 3) patients without
chronic P. aeruginosa infection including patients with inter-
mittent P. aeruginosa colonisation [2] and 4) patients harbouring
either Achromobacter xylosoxidans or the Burkholderia cepacia
complex are individually isolated from all other CF patients.
Patients are segregated in the outpatient clinic, in the wards, and
at social events, such as summer and winter camps. This policy
has successfully reduced the incidence of P. aeruginosa col-
onization and infection [21] and maintained a low incidence
of bacteria belonging to A. xylosoxidans and the B. cepacia
complex [22].2.2. Colistin policy
To promote the goal of maintaining lung function and de-
crease inflammation, treatment of all patients with chronic
P. aeruginosa lung infection with inhaled colistin (2 million
units twice daily) between regular intravenous antibiotic courses
was adopted as standard practice at the Danish CF centre in
Copenhagen in 1984 [4]. Since 1989, all intermittent colonised
patients have been treated with oral ciprofloxacin in combination
with colistin inhalation, in the beginning for 3 weeks, and since
1995 for 3 months (early eradication) every time P. aeruginosa
was isolated from the respiratory tract, to prevent or delay onset
of chronic infection [23]. Colistin was also from time to time
used intravenously while the chronically infected patients were
admitted to the hospital for treatment. In 1995, after 11 years
of colistin use, colistin resistant non-mucoid P. aeruginosa were
identified for the first time in the chronically infected population.
In patients from whom resistant strains had been isolated, we
adopted a policy of discontinuing colistin inhalation and re-
placing this with tobramycin inhalation until the resistant strain
had not been cultured from the patients sputum for 6 months.
This strategy has successfully been used to combat a previous
epidemic of multi-resistant non-mucoid P. aeruginosa in our
clinic [19]. Furthermore, patients harboring colistin resistant
strains were isolated from the other CF patients for 6 months.
Isolation arrangements were ceased after the patient had been
free from colistin resistant P. aeruginosa for a period of 6 months.
To decrease selection pressure, the use of inhaled colistin was
prohibited in the CF ward [19].
2.3. Microbiology
Since 1968, when the CF centre in Copenhagen was es-
tablished, sputum samples have been investigated everymonth by
Gram-stained smears and aerobic cultures on selective media.
These media include a Sabouraud plate, a 7% NaCl plate, a
B. cepacia plate containing colistin and gentamicin and a “blue
plate” (modified Conradi Drigalski's medium) selective for
Gram-negative rods and non-selective media including 5%
Danish blood agar and chocolate agar. Isolated bacteria were
identified as described previously [2]. Direct plating of sputum
samples on a 14 cm blood agar plate (State Serum Institute,
Copenhagen, Denmark) with discs containing anti-pseudomonas
antibiotics including colistin are used for primary susceptibility
testing and for detection of resistant mutants [2]. In 1991, we
decided to collect non-mucoid and mucoid P. aeruginosa isolates
from all the CF patients in our clinic every second year to follow
the development of resistance to all antibiotics used in the CF
ward. The antibiotics include colistin, tobramycin, meropenem,
ciprofloxacin, aztreonam, piperacillin/tazobactam and ceftazi-
dime. The minimal inhibitory concentration (MIC) determination
on the collected isolates is done by the agar dilution method
on Müller–Hinton agar. This method differs from the monthly
routine susceptibility testing of the sputum samples in the labo-
ratory, where the agar diffusion method is used on Danish blood
agar plates (Statens Serum Institut, Copenhagen, Denmark), em-
ploying Neosensitabs® (Rosco, Roskilde, Denmark) [24]. A
393H.K. Johansen et al. / Journal of Cystic Fibrosis 7 (2008) 391–397colistin resistant isolate is suspected in the routine laboratory
when the zone diameter around a polymyxin-containing disc
(150 μg polymyxin) is b 18 mm (MIC N 32 μg/ml).
2.4. Patient data
The epidemiological, microbiological and clinical data were
collected retrospectively from the patients' medical records.
The data used in the present study include: age of the patient,
gender, CF genotype, age at onset of chronic P. aeruginosa
lung infection, number of years in treatment with colistin,
doses, alternative treatments, number of years with chronic
P. aeruginosa lung infection before acquisition of colistin
resistant P. aeruginosa, age at acquisition of colistin resistant
P. aeruginosa, number of days to clearance of resistant isolates,
lung function and precipitating antibodies. In 7 selected patients
who had colistin resistant P. aeruginosa in 1995 and from
whom we also cultured the resistant isolate in 1997 or 1999
and again in 2004, the development in lung functions variables
were evaluated over time, to detect possible adverse effects
on lung function after long-term infection with colistin resistant
P. aeruginosa.
2.5. Pulsed-field-gel-electrophoresis (PFGE)
PFGE was used for bacterial genotyping and for identifying
clonality of colistin resistant P. aeruginosa isolates. We used
Spe I as restriction enzyme according to the methods described
previously [25,26] (Fig. 2). PFGE patterns were compared
visually and on the Gel Doc™ XR (Bio-Rad) and evaluated
using the criteria previously published [25–27]. Isolates with
differences in zero, one or two bands were considered identical;
other isolates were considered unrelated.
2.6. Mechanism of resistance
Mass spectral analysis of the lipid A moiety of lipopoly-
saccharide revealed that all strains lacked 2-hydroxylation of
laurate but had aminoarabinose added [8].
2.7. Statistics
A one-sample t-test was used for analyzing within-patient
changes.Table 1
Number of patients infected with colistin resistant non-mucoid P. aeruginosa in each
individual clones
Year Number of patients infected with colistin resistant
non-mucoid P. aeruginosa
Number of patients wit
P. aeruginosa lung infe
1995 9 109
1997 15 (4 colonised in 1995) 106
1999 12 (1 also colonised in 1995, 3 also colonised
in 1997, 1 also colonised in 1995 and 1997)
100
2004 23 newly colonised and 17 previously colonised 95
a 6 isolates were not genotyped due to technical difficulties, e.g. bacterial death.3. Results
All colistin resistant P. aeruginosa isolates in the first and
second outbreak were of the non-mucoid phenotype. The patients
who had colistin resistant isolates in the first outbreak had been
chronically infected with P. aeruginosa for a median of 16 years
(range 4–24 years). They had been treated with inhaled colistin
for a median of 10 years (range 5–15 years), and one had, in
addition, been treated with intravenous colistin for 16 days. The
first colistin resistant P. aeruginosa isolate emerged in our clinic
in 1995. A total of 27 patients had colistin resistant P. aeruginosa
in the first outbreak (1995–1999), 19 patients had a colistin re-
sistant P. aeruginosa in a single year only, either in 1995, 1997 or
1999, whereas eight had growth in multiple years (Table 1). Only
one of the patients had a colistin resistant isolate in all three years.
The median age of the patients was 24 years (range 9–37 years)
and they were infected for a median of 75 days (7–790 days).
Based on PFGE two large clusters and seven individual strains
were identified. The large clusters comprised 16 (cluster 1) and 5
patients (cluster 2), respectively (repetitions not included) (Fig. 1).
In the first outbreak, no significant change in lung function
as defined by FEV1 or FVC% predicted (p=0.98 and p=0.43,
respectively) or in P. aeruginosa precipitating antibodies
(p=0.44) was observed, when compared to the patients' own
lung function and precipitins one year before colistin resistance
was discovered till one year after the patients had cleared their
resistant isolates. Twenty-one of the 27 patients (78%) were
ΔF508 homozygotes, 4 wereΔF508 heterozygotes and 2 patients
had an unknown genotype. This distribution fits with the overall
genetic composition in our clinic.
In the period 2000 to 2004 we did not detect any colistin
resistant P. aeruginosa neither in our routine laboratory nor by
the biannually MIC investigations. However, during 2004 we
realized that this particular strain had reemerged in our clinic.
We found colistin resistant P. aeruginosa in 23 patients who had
never been infected with the resistant isolate and in 17 patients
from whom we had growth of colistin resistant P. aeruginosa in
the first outbreak period. This corresponds to 14% of all our CF
patients (40 of a total of 280) and 42% of all patients chronically
infected with P. aeruginosa (40 out of 95 patients). In contrast
to the first cohort, these newly colonised patients had been
chronically infected with P. aeruginosa for a much longer time
period (median 26 years, range 9–33 years) and they were




in the CF centre
Number of patients infected with
cluster 1, 2 or with individual clones
248 6, 2,1
260 9, 3, 3
271 6, 3, 3
280 15, 13, 6 a
Fig. 1. Pulsed-field-gel-electrophoresis (PFGE) pattern of 12 colistin resistant
non-mucoid Pseudomonas aeruginosa isolates from cluster 1 in the first
outbreak (1995–1999), from 10 CF patients. The Spe restriction enzyme was
used. Lane 1: molecular-weight standard, lane 2: pt #1, lane 3+4: pt #2 lane 5: pt
#3, lane 6: pt #4, lane 7+8: pt #5, lane 9: pt #6, lane 10: pt #7, lane 11: pt #8, lane
12: pt #9 and lane 13: pt #10, K (control): PAO1.
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inhaled colistin for a median of 17 years (range 10–21 years).
The CF genotype distribution was similar to the overall genetic
distribution in our clinic, 18 of the 23 patients were ΔF508
homozygotes (78%) and 5 were ΔF508 heterozygotes. There
was a slight median decline in P. aeruginosa precipitating
antibodies of one (range 0 to −5) among patients infected in
2004, from one year before to one year after colistin resistant
P. aeruginosa was identified (pb0.001). The majority of the
isolates in the second outbreak belonged to the two large
clusters (cluster 1: 6 patients and cluster 2: 8 patients) detected
in the initial outbreak and three individual strains. Patients
continued to be infected with isolates that belonged to the same
cluster over time, and no changes from one cluster to another
were seen.
In contrast to the first outbreak, patients in the second
outbreak had a significant decline in lung function as defined by
FEV1 or FVC% predicted (pb0.001 and pb0.003, respectively)
when compared to the patients' own lung function one year
before colistin resistance was discovered. In order to show
possible adverse effects of being colonised for a longer period
of time with the colistin resistant P. aeruginosa we also looked
at FEV1 or FVC% over time in a small group of 7 patients who
were infected with colistin resistant P. aeruginosa in the first
outbreak in 1995 and also infected in 2004 when the same
isolate reoccurred. We found that they had a median decline in
FEV1 of −1.1% (range +0.8 to −2.7%) per year during the
10 years where they had been intermittently infected with the
colistin resistant isolate and a median decline in FVC of −1.3%
(range +0.2 to −3.5%) per year.
The MICs for the colistin resistant isolates varied between
50 μg/ml and 400 μg/ml in the first outbreak and between
100 μg/ml and 400 μg/ml in the second outbreak. The geo-
metric mean MIC of colistin of the non-mucoid susceptible
isolates varied from 4.2 to 6.1 μg/ml and for mucoid isolates
from 1.6 to 2.5 μg/ml from 1995 to 2005, respectively. The
overall susceptibility pattern of the colistin resistant isolates
against other anti-pseudomonal antibiotics used routinely in
the CF ward did not differ when compared to the colistin
susceptible non-mucoid isolates.At the most recent MIC investigations of all P. aeruginosa
isolates from chronically infected CF patients (2006 and 2007),
none of the patients had cleared the colistin resistant Pseudo-
monas and no new patients had become colonised.
4. Discussion
Outbreaks of multi-resistant Gram-negative bacteria as well
as transmission between CF patients have been reported before
[11,22,28]. The present study underlines that although the
patients are cohort isolated according to the susceptibility of the
infecting P. aeruginosa there is a risk of other emerging infec-
tions within the cohorts [29,30], since it is known that exchange
of strains with selective advantages occur within the CF cohort
[19,31,32]. This biphasic outbreak has been going on for more
than 12 years and in spite of cohort isolation of the patients since
1981 new outbreaks can still occur. There was long follow-up
after this outbreak and fortunately, the clinical consequences for
the patients were small. However, transmission of resistance
genes to mucoid P. aeruginosa may occur and could have more
serious consequences for the patients, as well as spread to newly
colonised patients who are treated with inhaled colistin for their
initial and subsequent eradication therapy.
Resistance to colistin can occur either by inducible physio-
logical resistance (tolerance) in response to membrane stresses
such as divalent cation limitation or polymyxin exposure
(colistin) or constitutively due to mutations in pmrB [8,33]. In
both cases the mechanism is mediated through addition of an
aminoarabinose to lipid A in the P. aeruginosa LPS molecule.
The physiological resistance requires presence of colistin and is
based upon a pmrAB two component regulatory system, whereas
the constitutive expression leads to stable production of amino-
arabinose LPS not depending upon the presence of colistin [8].
When the colistin resistant P. aeruginosa isolates first
appeared in our routine laboratory, we did not pay much
attention to it. It had been suggested that “colistin resistance is
reversible and develops only rarely” [34] and that “resistance to
polymyxin acquired in vitro probably has no relevance to the
clinical situation, in which strains of P. aeruginosa have
retained their susceptibility in hospital environments where the
antibiotic has been much used” [35]. We perform monthly
routine susceptibility testing of the sputum samples in the
laboratory by the agar diffusion method on Danish blood agar
plates. The blood agar medium contains 0.72 mmol/l of calcium
chloride and 0.59 mmol/l of magnesium sulfate [36]. In
contrast, we measure MICs biannually on Müller–Hinton agar
that has a content of 2.05 mmol/l calcium chloride and
2.15 mmol/l magnesium sulfate. It has been shown that high
degrees of resistance to polymyxin can be obtained by growing
P. aeruginosa in a magnesium-deficient medium or in a calcium
rich medium [34]. The difference in calcium and magnesium
contents between the two culture mediums may explain the
different susceptibility findings. When we culture the isolates
on blood agar plates they are susceptible to colistin whereas
using Müller–Hinton agar the MIC of the isolates are 2–3 fold
higher to colistin. A similar problem concerning P. aeruginosa
and susceptibility to aminoglycosides has been published
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directly with the concentration of ionized magnesium in the
medium and that both ionized calcium and soluble magnesium
fractions control the inhibition zone sizes [37].
Fortunately, all the colistin resistant P. aeruginosa we have
detected till now are non-mucoid. One reason for only detecting
non-mucoid resistant strains may be that they are mainly located
in the conductive zone of the respiratory tract where most of the
inhaled colistin is deposited [38] and therefore the selective
pressure on non-mucoid strains is higher than on mucoid strains
[39,40]. Furthermore, in mucoid isolates the uronic acid of
alginate binds cationic antibiotics [41].
In a study from our centre it was shown that 73 CF patients
who were followed from three years before chronic P.
aeruginosa infection to 10 years after chronic infection with
non-mucoid strains had progression of the lung disease that was
similar to patients not infected with P. aeruginosa [19,42]. This
observation may explain why we did not see any decrease in
lung function in the first cohort of colonised patients. In the
second cohort where the patients did not clear the resistant
isolates we found a significant decline in lung function after
colistin resistant P. aeruginosa was contracted. This may in part
be explained by the age of this cohort, as the second cohort was
as a median eight years older that the first cohort and had been
chronically infected with P. aeruginosa for a median of 10 years
longer than the first cohort, and the avoidance of colistin
inhalation may also have caused a more pronounced CF asso-
ciated lung disease.
However, the loss of lung function in the two groups did not
exceed the yearly median slope of decline of −4% for FEV1 and
−3% for FVC for non-azithromycin treated patients at that time
[43]. The group of patients followed over 10 years who
harboured colistin resistant P. aeruginosa isolates for several
years only had a minor loss of lung function over time.
One reason for the successful adaptation of the colistin
resistant P. aeruginosa among our CF patients could be thatFig. 2. The flowchart shows possible sources of transmission of colistin resistant Pduring a two-week course of anti-pseudomonal β-lactam
antibiotic therapy, the sensitive bacterial population decreases
in contrast to the pre-existing resistant sub-population [28]. It
seems most likely that the colistin resistant isolate was selected
during treatment and originated from a pre-existing resistant
sub-population in the lungs of the patients. All patients in the
outbreaks had been treated every day with inhaled colistin for at
least 5 years, and small bacterial subpopulations may emerge
during daily inhalations and exchange of resistant isolates may
happen when patients are seen in the outpatients' clinic or
admitted to the hospital ward for 14 days of intravenous anti-
biotic chemotherapy (Fig. 2).
In 1995, when we first identified colistin resistant P.
aeruginosa, it was limited to relatively few CF patients, but
when it reemerged in 2004 it had spread to approximately 40%
of all patients chronically infected with P. aeruginosa. A similar
development has been reported from our centre in the mid-
eighties where there was an epidemic of a non-mucoid P.
aeruginosa resistant to aminoglycosides, carbenicillin, ureido-
penicillins, ceftazidim, cefsoludin and imipenem. The isolate
was present in the centre at a low frequency in 1973 but at that
time it was susceptible to most antibiotics. However, during
therapy with ceftazidime the MIC of ceftazidime increase, and
high level of resistance to carbenicillin developed [19]. In both
cases, emergence of resistance suddenly appeared after
intensive selective pressure by antibiotics and it is most likely
that colistin resistance was induced by the intensive use of this
drug at the hospital and in the patients' home.
Two identical clusters have dominated both outbreaks
(1995–1999 and 2004-) and when a patient was infected with
one particular cluster, it remained the same when the patient had
a colistin resistant isolate at a subsequent occasion. When
colistin inhalation was discontinued in the first outbreak, the
resistant isolates became undetectable within a short period of
time and could not be cultured in routine microbiological
examinations of sputum. This indicates that only the sensitiveseudomonas aeruginosa among the nine CF patients initially infected in 1995.
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pressure disappeared. In the second outbreak, the resistant iso-
late was not cleared, probably because the resistant cluster now
dominated the bacterial population in the lungs [32]. This is in
accordance with the other CF study that reported on an outbreak
of colistin resistant P. aeruginosa [11].
The geometric mean MIC of the sensitive non-mucoid and
mucoid isolates towards colistin remained stable during the entire
study period. This is in accordance with the findings in a
randomized clinical trial comparing nebulized colistin with
tobramycin in CF patients. The authors found that after 4 weeks
of nebulized colistin the P. aeruginosa MICs remained un-
changed [44].
In conclusion, the cohort isolation technique used in our CF
centre involves a risk of spreading resistant clones within a
cohort. Until now, two such epidemics have occurred, which in
both cases were due to non-mucoid strains and did not lead to
severe clinical problems for the patients [19]. However, indi-
vidual isolation and avoidance of colistin use was necessary to
stop the epidemic.
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